The many discovery disputes between AbbVie and Boehringer Ingelheim (“BI”) over BI’s biosimilar of HUMIRA® (adalimumab) in the Delaware District Court are providing insight on the bounds of discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback